Disc Medicine says RESTORE-PV Phase 2 trial shows DISC-3405 cuts phlebotomy needs in polycythemia vera patients

Reuters2026/09/09 23:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Disc Medicine presented initial Phase 2 RESTORE-PV results for DISC-3405 in polycythemia vera at the 2026 SOHO meeting.
Data showed improved hematocrit control, fewer phlebotomies, improved symptoms; results reflect iron-restriction effects without relying on phlebotomy.
DISC-3405 was generally well tolerated; injection-site reactions were infrequent, mild, self-limited.
Results will be featured in an SOHO oral presentation on Sept. 10.
Disc expects a broader RESTORE-PV update, including initial Phase 1b sickle cell disease data, by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609091925PRIMZONEFULLFEED9823809) on September 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Disc Medicine says RESTORE-PV Phase 2 trial shows DISC-3405 cuts phlebotomy needs in polycythemia vera patients

You may also like

Crypto prices